The EPS miss is significant and likely to pressure the stock near-term. Monitor the upcoming Goldman Sachs conference for any guidance updates or strategic commentary that could clarify the miss.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $8.11entry
- T+1 · 6mo ago +5.43%α +6.12% · $8.55
- T+5 · 5mo ago +13.44%α +16.41% · $9.20
- T+20 · 5mo ago +21.45%α +23.02% · $9.85
- T+60 · 3mo ago +72.26%α +71.14% · $13.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line with the $155.4M estimate). The press release focuses on an upcoming conference appearance, not guidance or operational details, leaving the miss as the primary takeaway.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of $0.15 missed consensus of $0.22 by 30.6%
- Revenue of $155.4M was in line with consensus of $155.4M
- No guidance update or operational commentary provided in the release
- CFO to present at Goldman Sachs Global Healthcare Conference on June 8, 2026
Financial Impact
EPS miss of $0.07 per share vs consensus, representing a 30.6% shortfall
Risk Factors
- No guidance or operational context provided, leaving the miss unexplained
- Potential for further downside if the miss reflects broader operational issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304982 |
Track record
18 reports on BVS
2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Viewing Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers